NurseJet
Back to Discover
Research ArticleResearchWorkflowQuality Improvement

YEARS was noninferior and avoided immediate CT angiography in 22% of cancer patients

JAMA (PubMed)Aug 25, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A multicenter randomized noninferiority trial found a YEARS-based diagnostic strategy was as safe as CT pulmonary angiography alone for suspected pulmonary embolism in active cancer and avoided immediate CT imaging in 22% of patients.

What NurseJet pulled from the source

The Hydra trial randomized 698 patients with active cancer and suspected pulmonary embolism at 21 hospitals. Among patients whose PE was ruled out initially, 90-day symptomatic venous thromboembolism or possible PE-related death met the prespecified noninferiority criterion for YEARS versus CTPA-only management. YEARS managed 77 of 352 patients without CTPA.

Why this matters for nurses

Oncology, emergency, and medical-unit nurses frequently initiate assessment and testing workflows for cancer patients with new dyspnea, chest pain, hypoxemia, or other possible PE features. The trial supports protocolized risk assessment while preserving prompt escalation for instability or changing symptoms.

Bedside takeaway

YEARS can reduce immediate CT imaging in eligible cancer patients when used within an approved diagnostic pathway.

How This Applies in Practice

Use this when: Caring for a patient with active cancer who is being evaluated for suspected acute pulmonary embolism.

On your shift

  • Escalate hemodynamic instability, hypoxemia, new chest symptoms, or other urgent findings through the PE response pathway.
  • Gather and document the clinical assessment elements and ordered D-dimer required by the organization's diagnostic algorithm.
  • Confirm that imaging or PE exclusion decisions are completed under the approved pathway and responsible clinician.
Keep in mind: YEARS should not be used independently or outside an approved cancer-specific pathway. Follow facility protocol and provider orders.

Key takeaways

  • The trial randomized 698 patients with active cancer and suspected acute pulmonary embolism.
  • A YEARS strategy using clinical items, D-dimer, and risk-dependent CTPA met the prespecified noninferiority criterion.
  • The YEARS pathway avoided immediate CTPA in 77 of 352 patients, or 22%.
  • The proportion of negative CTPA results did not differ significantly between groups.

Practice implications

  • Recognize and escalate possible PE promptly, collect the clinical information and ordered D-dimer needed for the approved pathway, and verify whether the organization permits YEARS in active cancer. Do not use the trial to independently rule out PE or defer imaging outside protocol.

Limitations & cautions

  • The study was open label, applied a prespecified noninferiority margin, and was conducted in 21 European hospitals. The result supports the tested pathway in eligible patients but does not validate unsupervised bedside use or every cancer population.
  • AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

JAMA (PubMed)

JAMA (PubMed). YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42437322/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Renal failure (PubMed)

A single-center retrospective cohort found that approximately one quarter of laboratory-defined acute kidney injury cases on internal medicine wards were not documented, particularly when maximal creatinine was lower.

Med-SurgAI summaryReview source

Pediatric emergency care (PubMed)

A double-blind randomized trial found no reduction in vomiting or faster oral tolerance with intravenous pantoprazole versus placebo in children with acute gastroenteritis and persistent vomiting after ondansetron.

PedsEmergencyAI summaryReview source

European heart journal (PubMed)

In the pragmatic TARGET-D randomized trial, vitamin D dosing titrated to a serum target did not significantly reduce the composite of death, recurrent myocardial infarction, heart-failure hospitalization, or stroke after myocardial infarction.

TelemetryMed-SurgAI summaryReview source